Parkinson’s Launch Announcement

Synapticure announces expansion into Parkinson’s Disease today, starting in 5 states

[Update: Synapticure has expanded to serve patients with Parkinson's Disease in the following states: Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Mississippi, Montana, New Jersey, New York, Pennsylvania, South Carolina, Texas, Washington, West Virginia, and Wisconsin.]

November 14, 2022 (Chicago, IL) — Synapticure, a telemedicine company that provides personalized, proactive care to patients and caregivers with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS), announced that it has expanded to serve Parkinson’s Disease, starting today with people living with Parkinson’s in Florida, Georgia, and Texas, California, and Illinois.

“High quality specialty care for a host of neurodegenerative diseases is hard to access and today we’re very excited to begin providing the very best medical care and support to Parkinson’s patients, building on what we have already done for the ALS and PLS community,” said Synapticure CEO and Co-Founder Sandra Abrevaya. “We are very fortunate to have a team of neurodegenerative clinical leaders at Synapticure who can bring care to every corner of the country, starting in Florida, Georgia, and Texas, California, and Illinois today.”

Synapticure’s Parkinson’s program will be run by Dr. Jaime Hatcher-Martin, who comes to Synapticure with 20 years of experience in Parkinson’s, including clinical trials examining inflammatory markers and potential therapeutics and basic science research on oxidative stress and environmental risk factors in Parkinson’s. “I am thrilled to be able to offer this incredible service starting today,” said Dr. Hatcher-Martin. “Synapticure will be a game changer in this sector, giving more patients with Parkinson’s Disease access to the comprehensive, personalized care they deserve, regardless of where they live in the United States.”

Synapticure is a fully virtual practice that makes care personalized and proactive by focusing on the issues that are most important to patients, including:

  • Performing virtual medical evaluations of patients with Synapticure neurologists trained in movement disorders
  • Providing patients with cutting-edge testing to help both patients and neurologists understand more about a patient’s specific disease subtype
  • Reviewing patient medication lists and discussing the risks and benefits of the various treatments available
  • Prescribing medications, therapies and equipment, including working though prior authorizations and appeals
  • Answering questions about nutraceuticals based on reputable science and sources
  • Providing decision making and enrollment support for clinical trials
  • Offering genetic testing from home with pre- and post-test counseling by Synapticure’s genetic counselors
  • Helping navigate insurance policies, explaining available SSDI, Medicare, Medicaid, Veteran’s benefits, commercial insurance plans and supplements, and long-term care policies
  • Providing frequent touch points to make sure patient needs and concerns are being addressed

Synapticure can provide this care as a primary neurologist or in partnership with any other doctors on a patient’s care team. Dr. Eric Anderson, Synapticure’s VP of Clinical Operations and Care Delivery, adds, “Building on the amazing success that our patient-centric chronic care model has had with the ALS population, an expansion of clinical services to other neurodegenerative diseases is natural, and we are very excited to work towards having a positive impact on those living with Parkinson's disease next.”

Synapticure’s medical group, CareND is contracted with Medicare, Blue Cross Blue Shield, Selecthealth and Friday Health Plans, with more plans contracting with CareND every week. If CareND is not contracted with a specific plan, they will submit a bill to that plan as an out-of-network provider. The benefit coverage for care provided by CareND is determined solely by a patient’s insurance company and is based on the provisions of a patient’s specific medical benefit plan. Synapticure’s billing team will provide an estimate of any co-pay prior to the visit. If a patient does not have health insurance or wants to pay out of pocket for the visit, Synapticure’s billing team informs patients of the cost prior to the visit.

Patients living in Florida, Georgia, and Texas, California, and Illinois can sign up here to learn more. Synapticure plans to expand quickly to provide care to all states across the US, and invites anyone living with Parkinson’s nationwide to sign up here for updates on our expansion into additional states.

For all inquiries, please contact
Winona Koldyke

About Synapticure
Synapticure is dedicated to creating the future of neurodegenerative disease patient care. Today, Synapticure is focused on providing better treatment and care for all people living with ALS through a full-stack teleneurology platform, built by and for those living with ALS. Co-founded by Brian Wallach, Sandra Abrevaya, Peter Wallach, Jason Langheier and Jonathan Hirsch, Synapticure is headquartered in Chicago, Illinois. To learn more, please visit or follow us on Twitter, LinkedIn, Facebook, and Instagram for updates.

About ALS
ALS is 100% fatal and affects more than 30,000 people in the U.S. The lifetime risk of developing ALS is 1 in 300, the same as Multiple Sclerosis. Each year, more than five thousand people are diagnosed with ALS in the US alone. This number is expected to nearly double by 2060. People living with ALS, on average, live two to five years after diagnosis, and nearly half live more than 50 miles away from the closest ALS multidisciplinary clinic.

About Parkinson’s Disease
Parkinson's disease is a progressive neurodegenerative disease that causes nerve cells (or neurons) in the area of the brain that controls movement to weaken and/or die. More than 10 million people worldwide are currently living with Parkinson's disease. The number of people diagnosed with with Parkinson’s Disease is expected to rise from 900,000 to 1.2 million by 2030. What causes Parkinson's remains largely unknown. Genetics cause about 10 to 15 percent of all Parkinson's. The other 85 to 90 percent of cases are classified as sporadic (or occasional). Although there is no cure, treatment options vary and include medications and surgery.